In patients with myeloproliferative neoplasms (MPNs), cardiovascular risk factors (CVRFs) appeared predictive of poorer overall survival (OS) and thrombosis in a study published in the journal Blood ...

Researchers examined use of disease-modifying therapies in women with multiple sclerosis during preconception, pregnancy, and postpartum.

The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.

About 80% of parents currently choose to follow CDC guidelines to vaccinate their babies for hepatitis B at birth.

Researchers assessed chronic opioid prescription dispensing among patients with gout in the United States.

Researchers evaluated whether chondrocalcinosis independently contributes to incident knee osteoarthritis and knee pain.

HealthDay News — The US Food and Drug Administration (FDA) has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).

In a prospective cohort study, researchers examined how early life medical risk factors for individuals born preterm compare with those born full-term in adulthood.

Researchers assessed whether a childhood asthma subgroup at high-risk for ARI could be identified using natural language processing algorithms as a “digital biomarker.” ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Private equity hospitals reduced ED and ICU salary expenditures after acquisition relative to control hospitals .

Researchers examined the association between levels of vitamin D and risk for MS among White and Black military personnel in the US.